Teduglutide for Enterocutaneous Fistula (ECF)

Teduglutide for Treatment of Enterocutaneous Fistula (ECF) - a Pilot Study to Demonstrate Safety and Feasibility

NCT02889393•Daniel Dante Yeh

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Postoperative Fistula

Interventions

Teduglutide

Standard of Care

Locations

United States

Locations (1)

University of Miami

Miami, Florida, United States

Key Dates

Start Date

January 31, 2019

Primary Completion Date

July 15, 2020

Completion Date

July 15, 2021

Last Updated

October 6, 2021

Sponsors

Lead Sponsor

Daniel Dante Yeh

Collaborators

Takeda

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions